DPP4 and Sepsis: Increased susceptibility to sepsis and poor outcomes after sepsis have been well documented in patients with diabetes and CKD.44,45 In the present study, we observed lower sepsis- and infection-related mortality in the GLP-1 receptor agonist group than in the DPP-4 inhibitor group.